Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b Open-Label, Multicenter Clinical Study of the Safety and Activity of Intravenous Administration of SNS-595 in Patients With Advanced Hematologic Malignancies

NCT00246662 is registered in ClinicalTrials.gov with Sunesis Pharmaceuticals as lead sponsor.

NCT NCT00246662
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00246662 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b Open-Label, Multicenter Clinical Study of the Safety and Activity of Intravenous Administration of SNS-595 in Patients With Advanced Hematologic Malignancies
Lead sponsor
Sunesis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
November 14, 2005
Completion date
April 30, 2009
Enrollment
75 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphocytic, acute, leukemia, myeloid, chronic, leukemia, nonlymphocytic, acute, myelodysplastic syndromes